Сравнение эффективности и токсичности режимов FC и FCR у первичных больных В-клеточным хроническим лимфолейкозом

1. Catovsky D, Richards S, Matutes E et al. UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370 (9583): 230–9.
2. Eichhorst BF, Busch R, Hopfinger G et al. German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107 (3): 885–91.
3. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–33.
4. Huhn D, von Schilling C, Wilhelm M et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98: 1326–31.
5. Manshouri T, Do KA, Wang X et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003; 101: 2507–13.
6. O'Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19 (8): 2165–70.
7. Di Gaetano N, Xiao Y, Erba E et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114 (4): 800–9.
8. Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin’s lymphoma by pentoxifylline and rituximab. Anticancer Res 2000; 20: 2961–6.
9. Demidem A, Lam T, Alas S et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177–86.
10. Byrd JC, Peterson BL, Morrison VA et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101 (1): 6–14.
11. Keating MJ, O'Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23 (18): 4079–88.
12. Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23 (18): 4070–8.
13. Rummel MJ, Stilgenbauer S, Gamm H et al.. Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia (CLL)-preliminary results of a randomised phase-III multicenter study. Blood 2002; 100 (11): 384a, abstract 1489.
14. O'Brien S, Kantarjian H, Beran M et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis derived prognostic model for response to treatment. Blood 1993; 82: 1695–700.
15. Bosch F, Perales M, Cobo F et al. Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL). Blood 1997; 90 (Suppl. 1): 530a, abstract 2360.
16. Tsimberidou AM, Keating MJ, Giles FJ et al. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 2004; 100 (12): 2583–91.
17. Byrd JC, Rai K, Peterson BL et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105 (1): 49–53.
18. Никитин Е.А., Пивник А.В., Судариков А.Б. и др. Сравнение форм хронического лимфолейкоза в зависимости от мутационного статуса генов вариабельного региона иммуноглобулинов. Тер. арх. 2000; 72 (7): 52–6.
19. Cheson BD Bennett JM et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–7.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31–41.
21. Keating MJ, O’Brien S, Lerner S et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165–71.

Е.А.Стадник2, Е.А.Никитин1, Б.В.Бидерман1, Г.Н.Салогуб2, Ю.Ю.Лорие1, Н.Н.Цыба1, Ю.А.Aлексеева2, В.А.Доронин4, В.Н.Мащук5, Р.И.Вабищевич3, А.Л.Меликян1, Т.И.Колошейнова1, Л.Ю.Колосова1, А.Б.Судариков1, Л.Г.Ковалева1, А.Ю.Зарицкий3

1 ГУ Гематологический научный центр РАМН;
2 Городская клиническая больница №31, Санкт-Петербург;
3 Федеральный центр крови, сердца и эндокринологии им. акад. В.А.Алмазова;
4 ЦКБ №2 Министерства путей сообщения; 5Краснодарский краевой онкодиспансер